Aurobindo Pharma Limited
Aurobindo Pharma Limited is an Indian listed company in the Pharmaceuticals & Biotechnology industry (Healthcare sector), traded under NSE: AUROPHARMA and BSE: 524804 (ISIN INE406A01037).
It has a market capitalisation of ₹94,171 crore, a last close of ₹1,621 on 2026-10-19, a one-year return of 47.3%.
Valuation: a price-to-earnings ratio of 25.37x, a price-to-book ratio of 2.49x, a dividend yield of 0.0%.
Profitability: return on equity of 9.9%, return on capital employed of 14.5%, an operating margin of 20.3%.
Growth: sales growth of 10.6% a year over three years, net profit growth of 22.1% a year over three years.
Balance sheet and ownership: debt-to-equity of 0.20x, promoter holding of 51.9%.
| Metric | Value |
|---|---|
| Market capitalisation | 94,171 |
| Last close | ₹1,621 |
| P/E (TTM) | 25.37x |
| P/B | 2.49x |
| Dividend yield | 0.0% |
| ROE (FY) | 9.9% |
| ROCE (FY) | 14.5% |
| Operating margin (TTM) | 20.3% |
| Sales growth, 3-year CAGR | 10.6% |
| Profit growth, 3-year CAGR | 22.1% |
| Debt / equity | 0.20x |
| Promoter holding | 51.9% |
| 1-year return | 47.3% |
Loading the live page with the price chart, financial history, shareholding and recent filings. Data is end-of-day and rebuilt nightly; nothing here is investment advice. Financial statements · What each metric means